Tectonic Therapeutic, Inc. Company Profile

Background

Overview

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCRs). The company leverages its proprietary GEODe™ (GPCRs Engineered for Optimal Discovery) technology platform to develop biologic medicines targeting GPCRs, aiming to address significant unmet medical needs where therapeutic options are limited or nonexistent.

Mission and Vision

Tectonic's mission is to redefine growth through unparalleled technological excellence, empowering businesses with innovative solutions that transcend boundaries and drive sustainable success in the digital age. The company envisions a future where technology seamlessly integrates with every aspect of business and life, serving as a catalyst for transformation and consistently pushing the boundaries of what's possible.

Primary Area of Focus

The company's primary focus is on developing biologic medicines targeting GPCRs, with a particular emphasis on areas of significant unmet medical need, such as pulmonary hypertension and hereditary hemorrhagic telangiectasia (HHT). By harnessing its GEODe™ platform, Tectonic aims to overcome existing challenges in GPCR-targeted drug discovery and modify the course of diseases.

Industry Significance

GPCRs are a large family of receptors that play a crucial role in various physiological processes, making them significant targets for therapeutic intervention. Tectonic's innovative approach to developing biologic medicines targeting GPCRs positions the company as a key player in the biotechnology industry, particularly in addressing complex diseases with high unmet needs.

Key Strategic Focus

Core Objectives

Tectonic Therapeutic's strategic focus includes:

• Advancing Clinical Programs: Progressing lead candidates, such as TX45 and TX2100, through clinical trials to establish safety and efficacy.

• Expanding Pipeline: Developing additional GPCR-targeted biologics to address a broader range of diseases.

• Leveraging Proprietary Technology: Utilizing the GEODe™ platform to enhance the discovery and development of GPCR-targeted therapies.

Specific Areas of Specialization

Tectonic specializes in:

• GPCR Modulation: Designing biologic medicines that modulate GPCR activity to treat diseases.

• Pulmonary Hypertension: Developing therapies for pulmonary hypertension, including Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF) and associated conditions.

• Hereditary Hemorrhagic Telangiectasia (HHT): Creating treatments for HHT, a genetic bleeding disorder.

Key Technologies Utilized

The company employs:

• GEODe™ Platform: A proprietary technology for the discovery and development of GPCR-targeted biologic medicines.

• Fc-Relaxin Fusion Proteins: Utilizing fusion proteins like TX45 to activate specific GPCRs.

Primary Markets or Conditions Targeted

Tectonic targets:

• Pulmonary Hypertension: Specifically Group 2 PH-HFpEF and PH associated with interstitial lung disease (PH-ILD).

• Hereditary Hemorrhagic Telangiectasia (HHT): A genetic bleeding disorder with no approved treatments.

Financials and Funding

Funding History

Tectonic Therapeutic has undergone significant financial developments:

• Reverse Merger and Financing: In June 2024, the company completed a reverse merger with AVROBIO, Inc., a biotechnology company, and a concurrent private placement financing of $130.7 million.

• Public Offering: The company went public on June 21, 2018, listing its shares on NASDAQ under the ticker symbol TECX.

Total Funds Raised

As of December 31, 2025, Tectonic reported cash and cash equivalents of approximately $253.8 million, providing a runway into the fourth quarter of 2028.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Intended Utilization of Capital

The capital raised is intended to fund ongoing and planned clinical trials, including:

• TX45 APEX Phase 2 Trial: Evaluating TX45 in patients with Group 2 PH-HFpEF.

• TX2100 Phase 1a Trial: Assessing TX2100 in healthy volunteers for the treatment of HHT.

• TX45 Phase 2 Trial in PH-ILD: Expanding the evaluation of TX45 to patients with PH associated with interstitial lung disease.

Pipeline Development

Key Pipeline Candidates

• TX45: A novel Fc-relaxin fusion protein targeting the RXFP1 receptor, currently in Phase 2 trials for PH-HFpEF and PH-ILD.

• TX2100: A VHH-Fc fusion antagonist antibody targeting the APJ receptor, in Phase 1a trials for HHT.

Stages of Clinical Trials or Product Development

• TX45: Phase 2 trials ongoing for PH-HFpEF and PH-ILD.

• TX2100: Phase 1a trial initiated in healthy volunteers for HHT.

Target Conditions

• TX45: Pulmonary Hypertension, including PH-HFpEF and PH-ILD.

• TX2100: Hereditary Hemorrhagic Telangiectasia (HHT).

Relevant Timelines for Anticipated Milestones

• TX45 APEX Phase 2 Trial: Topline results expected in 2026.

• TX2100 Phase 1a Trial: Topline results anticipated in Q4 2026.

Technological Platform and Innovation

Proprietary Technologies

• GEODe™ Platform: A proprietary technology for the discovery and development of GPCR-targeted biologic medicines.

Significant Scientific Methods

• Fc-Relaxin Fusion Proteins: Utilizing fusion proteins like TX45 to activate specific GPCRs.

• VHH-Fc Fusion Antibodies: Developing antibodies such as TX2100 targeting the APJ receptor.

Leadership Team

Key Executive Profiles

• Alise Reicin, M.D.: President and Chief Executive Officer. Dr. Reicin has over 20 years of experience in pharmaceutical R&D, having led teams at Merck, EMD Serono, and Celgene. She holds an M.D. with honors from Harvard Medical School.

• Daniel Lochner, M.B.A.: Chief Financial Officer. Mr. Lochner joined Tectonic in June 2024, bringing nearly 20 years of biotechnology experience. He previously served as CFO and CBO for the Eye Care Division of Viatris Inc. and CFO and CBO of Oyster Point Pharma, Inc.

• Peter McNamara, Ph.D.: Chief Scientific Officer. Dr. McNamara has nearly 20 years of drug discovery experience, including roles at the Genomics Institute of the Novartis Research Foundation. He earned his Ph.D. in Biochemistry from the National University of Ireland at Galway.

• Anthony Muslin, M.D.: Chief Development Officer. Dr. Muslin has over 10 years of experience in pharmaceutical R&D, having led teams at Sanofi and Novartis. He holds an M.D. from Harvard Medical School.

• Marcella Kuhlman Ruddy, M.D., M.S.: Chief Medical Officer. Dr. Ruddy has over 15 years of experience in drug development, including roles at Regeneron Pharmaceuticals and Merck. She holds an A.B. from Princeton University and an M.D. from Washington University.

Leadership Changes

• François Nader, M.D., MBA: Appointed as an independent director to the Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board.